Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;33(7):e5857.
doi: 10.1002/pds.5857.

Use of Azithromycin Attributable to Acute SARS-CoV-2 Infection

Carlo Gagliotti  1   2 , Federico Banchelli  1   2 , Rossella Buttazzi  1   2 , Enrico Ricchizzi  1   2 , Lorenzo Maria Canziani  3 , Maurizia Rolli  1 , Evelina Tacconelli  3 , Maria Luisa Moro  2 , Elena Berti  1   2
Affiliations

Use of Azithromycin Attributable to Acute SARS-CoV-2 Infection

Carlo Gagliotti et al. Pharmacoepidemiol Drug Saf. 2024 Jul.

Abstract

Purpose: In the early stages of the COVID-19 pandemic, preliminary results that later proved to be incorrect suggested the possible efficacy of anti-infective drugs such as azithromycin for the treatment of SARS-CoV-2 infection. These preliminary data may have influenced the prescription of azithromycin. However, no individual-level data linking the use of this antibiotic to acute SARS-CoV-2 infection are available. The present analysis aims to fill this gap.

Methods: A retrospective population-based cohort design was used including patients diagnosed with SARS-CoV-2 infection in the period ranging from February 2020 to February 2022. The data source for antibiotic consumption was the drug database of outpatient prescriptions of Emilia-Romagna Region (Italy). Antibiotics were classified according to the Anatomical Therapeutic Chemical (ATC) classification system. Consumption rates and percentages of azithromycin DDDs (defined daily doses) during the acute phase of the infection were compared with a previous control period and with the post-acute phase. Analyses were stratified by four groups according to the prevalent virus variant at time of diagnosis.

Results: Comparing the previous control period with the acute phase of infections, the rates of azithromycin consumption (DDD per 1000 individuals per day) increased from 1.17 to 23.11, from 0.80 to 33.03, from 0.81 to 21.01, and from 1.02 to 9.76, in the pre-Alpha, Alpha, Delta, and Omicron periods, respectively. Similarly, the percentages of individuals receiving azithromycin, and the azithromycin DDDs percentages over total systemic antibiotics DDDs increased in acute phases of infection compared with control periods. The consumption rates and percentages returned to preinfection levels in the post-acute phase. In the study period, 12.9% of the use of azithromycin in the entire adult population of Emilia-Romagna was attributable to acute SARS-CoV-2 infection.

Conclusions: Considering the low likelihood of bacterial coinfections, the increased azithromycin consumption in the acute phase of SARS-CoV-2 infection suggests inappropriate prescribing of this antibiotic.

Keywords: ORCHESTRA project; SARS‐CoV‐2 infection; attributable use; azithromycin; defined daily dose; population‐based cohort.

PubMed Disclaimer

References

    1. L. D. Högberg, V. Vlahović‐Palčevski, C. Pereira, K. Weist, D. L. Monnet, and ESAC‐Net Study Group; ESAC‐Net Study Group Participants, “Decrease in Community Antibiotic Consumption During the COVID‐19 Pandemic, EU/EEA, 2020,” Euro Surveillance 26 (2021): 2101020, https://doi.org/10.2807/1560‐7917.ES.2021.26.46.2101020.
    1. P. Gautret, J. C. Lagier, P. Parola, et al., “Hydroxychloroquine and Azithromycin as a Treatment of COVID‐19: Results of an Open‐Label Non‐randomized Clinical Trial,” International Journal of Antimicrobial Agents 56, no. 1 (2020): 105949, https://doi.org/10.1016/j.ijantimicag.2020.105949.
    1. C. E. Oldenburg, B. A. Pinsky, J. Brogdon, et al., “Effect of Oral Azithromycin vs Placebo on COVID‐19 Symptoms in Outpatients With SARS‐CoV‐2 Infection: A Randomized Clinical Trial,” Journal of the American Medical Association 326 (2021): 490–498, https://doi.org/10.1001/jama.2021.11517.
    1. PRINCIPLE Trial Collaborative Group, “Azithromycin for Community Treatment of Suspected COVID‐19 in People at Increased Risk of an Adverse Clinical Course in the UK (PRINCIPLE): A Randomised, Controlled, Open‐Label, Adaptive Platform Trial,” Lancet 397 (2021): 1063–1074, https://doi.org/10.1016/S0140‐6736(21)00461‐X.
    1. The Medicines Utilisation Monitoring Centre (AIFA), National Report on Antibiotics Use in Italy. Year 2021 (Rome: Italian Medicines Agency (AIFA), 2023), https://doi.org/10.3390/antibiotics11010018.